Interview with professor Lisa K. Hicks: Patients with blood cancers, particularly those with more advanced disease, are at increased risk for serious COVID-19 outcomes, including an elevated chance of severe illness or death from infection, according to an analysis of more than 1,000 patients in the ASH RC COVID-19 Registry for Hematology.

Video: https://congressreport.eu/scientific-contents/interview:risks-hospitalization-and-death-among-patients-blood-disorders-ash-rc-covid-19-registry-hematology

Professor Srdan Verstovsek speak about the novelties and state of the art treatment presented at ASH 2021.

Video: https://congressreport.eu/scientific-contents/interview:novelties-treatment-myelofibrosis-and-polycythemia-vera-2021

Professor Virginia Kaklamani speak about the novelties and state of the art treatment presented at SABCS 2021.

Video: https://congressreport.eu/scientific-contents/interview:highlights-san-antonio-breast-cancer-symposium-2021

Professor Susanne Saussele speaks about antibody response to vaccination with BNT162b2, mRNA-1273, and ChADOx1 in Patients with Myeloid and Lymphoid Neoplasms. In general, patients with hematological diseases are predisposed to develop infections. Severe COVID-19 infection associated with high mortality is more likely in these patient cohorts compared to the general population. Due to immune defects related to the primary disease and/or to immunosuppressive treatment regimes, vaccination efficacy may be reduced in patients with hematological diseases. So far, data on this area are limited.

Video: https://congressreport.eu/scientific-contents/interview:antibody-response-vaccination-myeloid-and-lymphoid-neoplasms

Professor Javier Cortes speaks about the final results of KEYNOTE-355 trial, a Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.

Video: https://congressreport.eu/scientific-contents/interview:final-results-keynote-355

Professor Manali Kamdar speaks about Lisocabtagene Maraleucel, a CD19-Directed Chimeric Antigen Receptor T Cell Therapy, Versus Standard of Care with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation As Second-Line Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma.

Video: https://congressreport.eu/scientific-contents/interview:results-randomized-phase-3-transform-study

The main topics that Professor Umberto Vitolo speaks about: CAR T-cell studies, POLARIS study, R-CHOP timing.

Video: https://congressreport.eu/scientific-contents/interview:novelties-treatment-non-hodgkin-lymphoma-2021

Professor Lisa A. Carey speaks about the MONALEESA-2, -3, and -7 trials of ribociclib + endocrine therapy in patients with HR+/HER2− advanced breast cancer.

Video: https://congressreport.eu/scientific-contents/interview:correlative-analysis-overall-survival-intrinsic-subtype-across-monaleesa-2-3-and-7-studies

Professor Michael Gnant speaks about the final results from 5,760 patients in the randomized phase III PALLAS trial.

Video: https://congressreport.eu/scientific-contents/interview:pallas-trial-adjuvant-palbociclib-hrher2-early-breast-cancer

Professor Sara Hurvitz speaks about trastuzumab deruxtecan vs. trastuzumab emtansine in patients with HER2+ metastatic breast cancer.

Video: https://congressreport.eu/scientific-contents/interview:destiny-breast03-trial